Personalis Stock Price, News & Analysis

Personalis (PSNL) announced significant clinical results demonstrating the effectiveness of its NeXT Personal blood test in monitoring triple negative breast cancer (TNBC) patients. The data from PREDICT DNA and SCANDARE studies shows that the ultrasensitive circulating tumor DNA (ctDNA) test can identify high-risk patients for relapse after neoadjuvant therapy. Key findings revealed that patients with detectable ctDNA post-neoadjuvant therapy were approximately 10 times more likely to relapse, and those with post-surgical ctDNA detection were over 85 times more likely to experience recurrence. The test demonstrated 100% detection rate in pretreatment samples and showed particular strength in ultrasensitive detection below 100 PPM. The results suggest NeXT Personal could be instrumental in guiding clinical decisions for additional adjuvant therapies, with potential implications for reimbursement coverage in breast cancer monitoring.

Personalis (NASDAQ: PSNL) announced multiple presentations at the upcoming ASCO Annual Meeting in Chicago, showcasing new clinical data for their NeXT Personal® ultrasensitive ctDNA assay. The presentations focus on detecting residual and recurrent cancer across various applications, including breast cancer and cervical cancer.

The company will present four studies: a clinical science symposium on circulating tumor DNA in breast cancer (PREDICT-DNA trial), an oral presentation on ctDNA detection in locally advanced cervical cancer (CALLA trial), and two poster presentations covering triple-negative breast cancer post-chemotherapy and immunotherapy monitoring in advanced cancer.

Personalis (NASDAQ: PSNL), a company specializing in advanced genomics for precision oncology, has announced its management team's participation in the upcoming Craig-Hallum 22nd Annual Investor Conference. The event is scheduled to take place on Wednesday, May 28, 2025, and will be held at The Depot Renaissance Hotel in Minneapolis, MN.

Personalis (PSNL) reported Q1 2025 financial results with revenue of $20.6 million, up 6% year-over-year. The company delivered 2,184 molecular tests, a 52% sequential increase. Pharma tests and services revenue grew 39% to $13.6 million, while population sequencing revenue decreased 29% to $6.7 million. Gross margin improved to 35% from 28.1%. The company reported a net loss of $15.8 million ($0.18 per share). Notable achievements include positive results from NeXT Personal studies in colorectal and breast cancer, with 100% detection rate for eventual recurrences. For full-year 2025, Personalis expects revenue of $80-90 million and projects a net loss of approximately $83 million. The company ended Q1 with $185.7 million in cash and equivalents.

Personalis announced breakthrough results from their VICTORI cancer study, demonstrating that their NeXT Personal assay achieved 100% success in detecting colorectal cancer relapses before traditional imaging methods. The study, conducted at BC Cancer in Vancouver, analyzed blood samples from 71 patients with Stage I-IV colorectal cancer.

Key findings include:

• 100% detection rate of cancer recurrence before imaging confirmation
• 87% of relapses detected within 8 weeks post-surgery
• 85% of cases detected by 4 weeks post-surgery
• 100% accuracy in identifying disease-free patients
• Successful detection of distant metastases, including challenging lung metastasis
• 70% of initial detections were ultra-sensitive, with measurements as low as 2.45 PPM

The study, with a median follow-up of 15.75 months, highlights the potential of ctDNA-based liquid biopsies to help identify patients needing additional treatment while potentially helping others avoid unnecessary chemotherapy. The research continues as researchers aim to improve early cancer recurrence detection and treatment.

Personalis (Nasdaq: PSNL), a leader in advanced genomics for cancer, has scheduled the release of its first quarter 2025 financial results on Tuesday, May 6, 2025. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day to discuss the results and recent highlights.

Participants can join the call by dialing 877-451-6152 (domestic) or 201-389-0879 (international). The webinar will be accessible through the Events section on the company's investor website, with a replay available shortly after the call.

Personalis (Nasdaq: PSNL) has announced upcoming presentations of data for their NeXT Personal® ultrasensitive ctDNA assay at the AACR Annual Meeting (April 25-30, 2025) in Chicago. The presentations will showcase the test's capabilities in detecting residual and recurrent cancer.

Two oral presentations will feature: (1) preliminary results from the VICTORI study on post-surgical minimal residual disease detection in colorectal cancer, presented by Emma Titmuss from BC Cancer, and (2) ultrasensitive MRD detection results from the TRACERx study on early-stage lung cancer, presented by Charles Swanton from The Francis Crick Institute.

Additionally, a poster presentation will showcase clinical NeXT Personal testing results across more than 15 cancer types, demonstrating the test's impact on MRD detection in real-world clinical patient testing.

Personalis (Nasdaq: PSNL), a leading company in advanced genomics for precision oncology, has announced its management team's upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The event is scheduled for Wednesday, April 9, 2025.

Personalis (Nasdaq: PSNL) has published groundbreaking study results in Annals of Oncology, showcasing their NeXT Personal® ultra-sensitive ctDNA blood test for breast cancer detection. The study, conducted with The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust, analyzed 78 early-stage breast cancer patients.

Key findings demonstrate that NeXT Personal detected cancer recurrence with 100% accuracy, approximately 15 months ahead of standard imaging, with some cases detected up to 5 years earlier. The test utilizes whole-genome sequencing to identify up to 1,800 tumor variants, achieving sensitivity down to 1 part per million of ctDNA. Notably, 39% of detections occurred in the ultra-sensitive range below 100 PPM.

The study included patients with triple-negative, HER2+, and HR+ breast cancers. Importantly, all patients who tested negative remained disease-free throughout the study period. This research is particularly significant given breast cancer's status as the most common cancer in the U.S., with projected 300,000 new cases and 40,000 deaths in 2024.